TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Epileptic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained~* Age 6-18 years (Weight ≥ 20 kg)~* Clinical diagnosis of epileptic encephalopathy~  * Subject with epilepsy and developmental impairment;~ * Epileptic activity itself contributes to severe cognitive and behavioural impairments~ * Patients will typically have already have trialed at least two standard therapies~* Females of childbearing age:~* Negative urinary pregnancy test at screening~* Agree to use effective contraception for the duration of the study~Exclusion Criteria:~* Inability of a parent or legal guardian to give informed consent for any reason.~* Known hypersensitivity to memantine hydrochloride~* Taking concomitant Amantadine, Ketamine or Dextromethorphan, Cimetidine, Ranitidine, Procainamide, Quinidine, Quinine, Hydrochlorothiazide, Anticholinergics, L-dopa, Anticoagulant,~* Any degree of renal impairment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Memantine Hydrochloride 10 mg Placebo (Type: ACTIVE_COMPARATOR): Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps
- Placebo Memantine Hydrochloride 10 mg (Type: PLACEBO_COMPARATOR): Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the clinical diagnosis of localization related epilepsy/focal seizure (International League Against Epilepsy 2010) with a history of an episode of seizure within 48 hours of presentation~* Treatment naïve patients or patients who had not taken any treatment for at least 3 weeks before inclusion.~Exclusion Criteria:~* History of any recent traumatic brain injury, cerebral ischemia/transient ischemic attack/stroke~* Patients with neuroendocrinal tumours~* History of any invasive neurosurgical /non-invasive neuropsychiatric procedure.~* Patients who are already under treatment for the presenting conditions.~* Medication history of psychoactive or central nervous system depressant drugs~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Healthy control (Type: NO_INTERVENTION): Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
- Carbamazepine group (Type: EXPERIMENTAL): Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
- Oxcarbazepine group (Type: EXPERIMENTAL): Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Local Anaesthetic in Colonic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients undergoing open colonic resection at MSC under the ERAS program.~Exclusion Criteria:~* Known sensitivity to the local anaesthetic agents~* Patients who prefer not to participate (no consent gained)~* ASA greater or equal to 4~* Rectal resection~* Formation of stoma~* Current use of systemic steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LA (Type: EXPERIMENTAL): Use of Ropivacaine
- Placebo (Type: PLACEBO_COMPARATOR): Use of 0.9% saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous patients who have an indication for office hysteroscopy~Exclusion Criteria:~* Parous patients, menopausal patients and patients with cervical pathology, and previous cervical surgery will be excluded from the study. Moreover, patients with severe vaginal bleeding, acute pelvic inflammatory disease, glaucoma, allergy to misoprostol, cardiac, liver or kidney diseases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Long interval misoprostol (Type: EXPERIMENTAL): A small envelope including two labeled plastic bags (A \& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
- Short interval misoprostol (Type: ACTIVE_COMPARATOR): A small envelope including two labeled plastic bags (A\& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C at screening \> 85 mg/dL~* Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes or poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab AMD (Type: EXPERIMENTAL): Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
- Evolocumab AI/pen (Type: EXPERIMENTAL): Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Velcade® in IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years of age or older.~2. Must have IgA nephropathy documented by kidney biopsy.~3. Must have greater than 1gm of proteinuria a day.~4. Must be on a stable dose of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blocking agent (ARB) for at least 4 weeks prior to screening.~Exclusion Criteria:~1. Low platelet count and neutrophil count within certain limits defined for enrollment.~2. Underlying peripheral neuropathy.~3. Having cardiac problems, such as myocardial infarction, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~4. Allergic to VELCADE®, boron or mannitol.~5. Female subjects who are pregnant or breast-feeding.~6. Recent use of investigational drug within 14 days before enrollment.~7. Having serious medical conditions and infections (including HIV,or hepatitis B or C) or psychiatric illness likely to interfere with participation in the study.~8. Diagnosed or treated for cancer within 3 years of participation in the study, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low-risk prostate cancer after curative therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velcade® therapy (Type: EXPERIMENTAL): Patients with greater than 1gm of proteinuria per day will receive Velcade®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Risk Reduction Among Young Adults With Asthma During Wildfire Smoke Events (TRAK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-26 years old~* Diagnosed with asthma by a health care provider~* Own a smart phone (Android or iOS platforms)~* Speak and read English~Exclusion Criteria:~* Already use the Smoke Sense app~* Had surgery within 3 weeks of the study start date~* Have a cardio-vascular condition~* Smoke~* Have or have had COVID 19 (that you're aware of)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The control group will receive incentives for study participation but will not be introduced to the Smoke Sense app.
- Smoke Sense (Type: EXPERIMENTAL): None
- Smoke Sense Plus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children enrolled in the target schools.~* Written informed consent obtained from the child's parent(s) if they agree to participate.~Exclusion Criteria:~* History of severe hypersensitivity (anaphylactic response) to egg products or previous FluMist~* FluMist is licensed exclusively for use in healthy individuals age 5-49 years. Therefore children for whom annual receipt of inactivated influenza vaccine for specific medical condition(s) is recommended will not be eligible. These conditions include:~* Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart disease, or hemoglobinopathy~* Immunosuppression of child~* Severe immunosuppression of a household member~* Pregnancy~* Past history of Guillian-Barre Syndrome~* Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin containing products for one month after FluMist administration~* Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4 weeks prior to receipt of FluMist~* Received anti-influenza medication in the past 48 hours~* Fever in the past 72 hours~* Moderate to severe nasal congestion (inability to breathe through the nose) or acute phase URI symptoms until the congestion has improved

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): FluMist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* meet the diagnostic criteria for FM established by the American College of Rheumatology~* have initial pain level equal to or greater than 3 on a NRS 0-10~* have stable medication use related to FM for at least 4 weeks~* be able to read, write, and understand the English language~Exclusion Criteria (all participants):~* pregnant or breastfeeding~* epilepsy or history of seizures~* presence of pacemakers and/or other implanted devices~Exclusion Criteria (subset of 12 participants who wil have fMRIs):~* conditions that would not permit an fMRI (e.g., certain types of metal or metallic objects in body, diaphragm or intrauterine device, dermal patches, ear or eye implants, implanted electrical stimulators, artificial heart valve, implanted catheter or tube, tattoos, claustrophobia; or weight more than 275 lbs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CES device (Type: ACTIVE_COMPARATOR): Participants will use the device for 60 minutes each day for 8 weeks.
- Sham device (Type: SHAM_COMPARATOR): Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
- Usual care alone (Type: NO_INTERVENTION): No intervention; participants will receive usual medical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real World Perspectives on Advancements in Hearing Aid Technology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate sensorineural hearing loss~* Experienced hearing aid user~* Has a significant other/communication partner that can fill out a questionnaire about hearing aid performance during the home trial~* Smartphone user for receiving study alerts~Exclusion Criteria:~* Cognitive impairment~* Not willing to wear hearing aid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Participants tested with comparator devices first, then Audeo Lumity devices (Type: EXPERIMENTAL): All participants who completed speech in noise testing in the lab with the comparator devices first, and then the Audeo Lumity devices.
- Participants who were tested with Audeo Lumity first, then comparator devices (Type: EXPERIMENTAL): All participants who completed speech in noise testing in the lab with the Audeo Lumity devices first, and then the comparator devices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Men's Sexual Risk Behaviors: Alcohol, Sexual Aggression, and Emotional Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Single~* Male~* Ages 21-30~* Engagement in unprotected intercourse with a woman at least once in the past year -~* Consumed alcohol at least 2 times per week in the past 30 days~* Had sex with a woman at least 2 times in the past 30 days~Exclusion Criteria:~* A history of alcohol problems~* A medical condition and/or medications which contraindicate alcohol consumption~* In a relationship that is monogamous and has lasted longer than 6 months

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Alcoholic beverage, High Provocation Manipulation (Type: EXPERIMENTAL): Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
- Non-alcoholic beverage, High Provocation Manipulation (Type: EXPERIMENTAL): Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
- Alcoholic beverage, Low provocation manipulation (Type: EXPERIMENTAL): Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants receive an experimental manipulation designed to evoke positive emotions.
- Non-alcoholic beverage, Low provocation manipulation (Type: EXPERIMENTAL): Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke positive emotions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficiency of Bumetanide in Autistic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the WHO ( CIM-10) and the parents of which gave a free, enlightened and written consent.~Exclusion Criteria:~* Patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system~* Patients autistics receiving a psychotropic treatment~* Patients presenting disorders electrolytes~* Patients presenting a hypersensibility known about sulpha drugs~* Presenting patients against indications relative to the treatment by bumetanide~* Patients already treated by diuretics~* Patients presenting a hepatic or renal incapacity~* Patients presenting an elongation of the QT to the electrocardiogram.~* Patients autistics of CARS sore is lower than 30.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Bumetanide (Type: EXPERIMENTAL): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete